Literature DB >> 6239684

Absence of generalized immunosuppression in C57BL/6J mice implanted with Lewis T241 fibrosarcoma or Lewis lung carcinoma.

C E Jones, C T Lee, W Skinner, P Koyama, D Prescott.   

Abstract

The immune status of C57BL/6J mice implanted with Lewis T241 fibrosarcoma or Lewis lung (LL) carcinoma was investigated on days 14 and 28 after implantation. Splenic lymphocyte responses were assessed in mitogen (Con A, LPS) mixed lymphocyte culture (MLC), natural killer (NK), graft-vs-host (GVH), and interleukin production assays. Except for NK-cell cytotoxicity, all other immunologic parameters were either comparable to those in medium-implanted controls or augmented. NK cytotoxicity was reduced in both tumor-bearing groups on day 28. The provision of NK potentiation therapy (beta-interferon, polyinosinic: polycytidylic acid) to T241 mice under various treatment conditions did not have any significant effect on lung metastasis or survival. The results of this study do not support the thesis that T241- or LL-bearing C57BL/6J mice are generally immunosuppressed. Indeed, when immune functions were assessed on the basis of total splenic activity, each of the measured immunologic parameters was substantially greater in animals with tumors than without. Further it seems improbable, considering the magnitude of the NK-cell defect in T241 mice on days 14 and 28 after implantation and the absence of a therapeutic response to NK-cell stimulants, that NK-cell cytotoxicity is intrinsically associated with resistance to tumor progression in this model.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6239684     DOI: 10.1007/bf00205739

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  15 in total

1.  Immunosuppressive effects of the Lewis lung carcinoma.

Authors:  P C Klykken; A E Munson
Journal:  J Reticuloendothel Soc       Date:  1979-06

2.  Studies of the thymus in mice bearing the Lewis lung carcinoma. II. Modulation of thymic natural killer activity by thymulin (FTS-Zn) and the antimetastatic effect of zinc.

Authors:  D Kaiserlian; W Savino; M Dardenne
Journal:  Clin Immunol Immunopathol       Date:  1983-08

3.  Correlation of immune response with clinical stage in Lewis lung tumor-bearing mice.

Authors:  T Kurata; M Micksche
Journal:  Oncology       Date:  1978       Impact factor: 2.935

4.  The stimulatory effect of tumor bearing upon the T- and B-cell subpopulations of the mouse spleen.

Authors:  S Konda; Y Nakao; R T Smith
Journal:  Cancer Res       Date:  1973-10       Impact factor: 12.701

5.  Inhibition of tumor growth in association with modification of in vivo immune response by indomethacin and polyinosinic:polycytidylic acid.

Authors:  M J Droller; D Gomolka
Journal:  Cancer Res       Date:  1982-12       Impact factor: 12.701

6.  Presence of suppressor cells in spleens of mice bearing a weakly immunogenic syngeneic tumor.

Authors:  S C Gautam; S D Deodhar
Journal:  Cancer Res       Date:  1979-08       Impact factor: 12.701

7.  Biology of cancer therapy: some new insights into adjuvant treatment of metastatic solid tumors.

Authors:  M G Hanna; M E Key; R K Oldham
Journal:  J Biol Response Mod       Date:  1983

8.  Simple method for quantifying pulmonary metastases in a murine fibrosarcoma.

Authors:  C E Jones; C T Lee; S D Deodhar
Journal:  Cancer Res       Date:  1983-12       Impact factor: 12.701

9.  Diminution of cyclophosphamide-induced suppression of antitumor immunity by an immunomodulator PS-K and combined therapeutic effects of PS-K and cyclophosphamide on transplanted tumor in rats.

Authors:  Y Mizushima; N Yuhki; M Hosokawa; H Kobayashi
Journal:  Cancer Res       Date:  1982-12       Impact factor: 12.701

10.  The induction of graft versus host disease in mice treated with cyclophosphamide.

Authors:  A H Owens; G W Santos
Journal:  J Exp Med       Date:  1968-08-01       Impact factor: 14.307

View more
  2 in total

1.  Role of macrophages in the host response to Lewis lung peritoneal carcinomatosis.

Authors:  M W Barth; P S Morahan
Journal:  Cancer Immunol Immunother       Date:  1994-04       Impact factor: 6.968

2.  Augmentation of natural cell activity in tumor-bearing and normal mice by MVE-2.

Authors:  W Budzynski; M Chirigos; E Gruys
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.